Given the FAST and FAST-Forward trial data, can we consider those ultra-hypofractionated whole breast radiation schemes to be standard of care for early-stage breast cancer?

With respect to FAST (28.5 Gy in 5 fx over 5 weeks), it can be considered based on 10-year data. Local control rates were low in all arms, but in general, I limit this to patients who can't do standard hypofractionated WBI (40/15).

FAST-Forward now has 10-year outcomes and can be considered for appro...

While there is only 5-year data, I am starting to use FAST-Forward in selected patients with significant transportation or COVID issues, and in whom I don't expect challenges achieving dose homogeneity with a 3D treatment plan. In the first few we've treated - I have followed weekly after treatment ...

Does P2026, favoring SBRT (?), in freestanding centers vs IMRT/3D, likely have an impact on use?